Literature DB >> 14597212

B lymphocytes from individuals with common variable immunodeficiency respond to B lymphocyte stimulator (BLyS protein) in vitro.

Donn M Stewart1, Michael J McAvoy, David M Hilbert, David L Nelson.   

Abstract

B lymphocyte stimulator (BLyS protein) is a member of the human TNF family of ligands. BLyS induces B-lymphocyte proliferation and Ig secretion in vitro and in vivo. These qualities suggest that it may be useful as a therapeutic in the treatment of immunodeficiencies characterized by low or absent serum immunoglobulin, such as common variable immunodeficiency (CVID). CVID is characterized by the inability to generate adequate serum Ig despite normal or slightly depressed peripheral B, T, and myeloid cell populations. We tested the ability of BLyS to stimulate B lymphocytes obtained from CVID patients. Among five patients studied, 60% (three of five) produced normal quantities of IgM when cultured in the presence of BLyS. B-cell proliferation among patients was comparable, with 60% (three of five) responding to BLyS stimulation. These results suggest that BLyS induces proliferative and Ig-secretory responses in B lymphocytes isolated from some CVID patients and lend support to its potential use in therapy of this disorder.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14597212     DOI: 10.1016/s1521-6616(03)00215-8

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  9 in total

1.  IL-2, IL-4, IFN-γ or TNF-α enhances BAFF-stimulated cell viability and survival by activating Erk1/2 and S6K1 pathways in neoplastic B-lymphoid cells.

Authors:  Lin Gui; Qingyu Zeng; Zhigang Xu; Hai Zhang; Shanshan Qin; Chunxiao Liu; Chong Xu; Zhou Qian; Shuangquan Zhang; Shile Huang; Long Chen
Journal:  Cytokine       Date:  2016-05-25       Impact factor: 3.861

2.  Mutational analysis of human BLyS in patients with common variable immunodeficiency.

Authors:  Claretta Gioia Losi; Ulrich Salzer; Roberta Gatta; Vassilios Lougaris; Gemma Cattaneo; Antonella Meini; Annarosa Soresina; Bodo Grimbacher; Alessandro Plebani
Journal:  J Clin Immunol       Date:  2006-06-01       Impact factor: 8.317

3.  Primary immune effects of eukaryotic expression plasmids encoding two hyperactive mutants of human soluble B lymphocyte stimulator.

Authors:  Guangyu Chen; Hongwu Du; Zhengjian Zhang; Shanyun Peng; Donggang Xu; Jiaxi Wang
Journal:  J Clin Immunol       Date:  2005-09       Impact factor: 8.317

4.  The discovery and development of belimumab: the anti-BLyS-lupus connection.

Authors:  William Stohl; David M Hilbert
Journal:  Nat Biotechnol       Date:  2012-01-09       Impact factor: 54.908

Review 5.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report.

Authors:  Juan Gea-Banacloche; Krishna V Komanduri; Paul Carpenter; Sophie Paczesny; Stefanie Sarantopoulos; Jo-Anne Young; Nahed El Kassar; Robert Q Le; Kirk R Schultz; Linda M Griffith; Bipin N Savani; John R Wingard
Journal:  Biol Blood Marrow Transplant       Date:  2016-10-14       Impact factor: 5.742

6.  Reduced BAFF-R and increased TACI expression in common variable immunodeficiency.

Authors:  Rita R Barbosa; Susana L Silva; Sara P Silva; Alcinda C Melo; M Conceição Pereira-Santos; João T Barata; Lennart Hammarström; Marília Cascalho; Ana E Sousa
Journal:  J Clin Immunol       Date:  2014-05-09       Impact factor: 8.317

7.  High serum levels of BAFF, APRIL, and TACI in common variable immunodeficiency.

Authors:  Adina K Knight; Lin Radigan; Thomas Marron; Allison Langs; Li Zhang; Charlotte Cunningham-Rundles
Journal:  Clin Immunol       Date:  2007-06-07       Impact factor: 3.969

8.  B-cell-activating factor and autoimmune myasthenia gravis.

Authors:  Samia Ragheb; Robert P Lisak
Journal:  Autoimmune Dis       Date:  2011-11-28

9.  Human BLyS facilitates engraftment of human PBL derived B cells in immunodeficient mice.

Authors:  Madelyn R Schmidt; Michael C Appel; Lisa J Giassi; Dale L Greiner; Leonard D Shultz; Robert T Woodland
Journal:  PLoS One       Date:  2008-09-11       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.